Ohr Pharmaceuticals, Inc. (OHRP)
(Delayed Data from NSDQ)
$2.65 USD
+0.05 (1.92%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.69 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
NeuBase Therapeutics, Inc. [OHRP]
Reports for Purchase
Showing records 1 - 20 ( 43 total )
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
ValuEngine Detailed Valuation Report for OHRP
Provider: ValuEngine, Inc
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
MAKO Results Come Out Negative; Downgrade to Neutral
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Treat Yourself Before MAKO Results in January; Affirm Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Cleantech - Industrial Growth
Provider: Roth Capital Partners, Inc.
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Docs Are Bullish on the Success of MAKO Trial; Affirm Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
OHRP YE17 Recap: Squalamine at the Finish Line While Others Dropped like Flies
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Healthcare -Will Squalamine Work For Wet-AMD In Upcoming MAKO Study Readout in Jan.?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Squalamine Remains Strong Wet-AMD Combo Player; Affirm Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Squalamine, There Is More than Meets the Eye; Initiating with Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
We are terminating coverage due to the departure from the firm of the covering analyst
Provider: H.C. Wainwright & Co., Inc.
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Riding the MAKO and Expect to Make Landfall in Early 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
We are dropping coverage due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
What Fovista''s Downfall Means for Ohr: Lesion Characteristics and Size Matters
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C